Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 I-Mab Cuts Workforce Following Portfolio Reprioritization  | Contract Pharma

What are you searching for?

Sign in
Breaking News

I-Mab Cuts Workforce Following Portfolio Reprioritization 

Reduces workforce by approximately 27% to focus resources on advancing lead program, givastomig.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

I-Mab, a U.S.-based global biotech company focused on the development of precision immuno-oncology agents to treat cancer, is reprioritizing its resources to focus on advancing its lead program, givastomig, a CLDN18.2 x 4-1BB bispecific antibody, targeting first-line metastatic gastric cancers, with further potential in other solid tumors.

I-MAB completed a workforce reduction as part of a Realignment Plan aimed at optimizing its operations following the pipeline reprioritization. The company reduced its workforce by approximately 27% and expects an annual savings of approximately $3 million.

With operations in Rockville, MD, and Short Hills, NJ, I-Mab had approximately 220 employees as of December 31, 2023. 

Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting CLDN18.2-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain a strong tumor-binding property and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with CLDN18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.

Meanwhile, the company is pausing development of uliledlimab (TJ004309), an antibody designed to target CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. I-Mab owns worldwide rights to uliledlimab outside of Greater China.

Ragistomig (TJ-L14B / ABL503), a bispecific, Fc-silent antibody designed to provide anti-PD-L1 activity and conditional 4-1BB-driven T-cell activation in one molecule, is being developed for solid tumors that are refractory or have relapsed after exposure to CPIs. The program is being jointly developed through a global partnership with ABL Bio, in which ABL Bio is the lead party and shares worldwide rights, excluding China and South Korea, equally with I-Mab.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics